Clinical Research

Black, rural and low-income PAD patients are less likely to receive high-quality care

"This research should be a call to health systems, policymakers and other stakeholders to make it easier for patients—especially the most vulnerable patients—to access PAD-specific care," one cardiologist explained. 

Thumbnail

Advanced MRI techniques may provide insight into brain damage stemming from youth sports

The study is part of a bigger effort to understand why some children recover better than others following head injuries.

Video of Clyde Yancy, MD, explaining new directions in treating heart failure with preserved ejection fraction.

Exploring the 'new era' of HFpEF treatment: More options exist, but challenges remain

Clyde Yancy, MD, spoke with Cardiovascular Business about how the treatment of heart failure with preserved ejection fraction (HFpEF) has evolved in recent years.

Thumbnail

Altered brain structure may play a role in eating disorders, MRI data suggest

Experts recently uncovered evidence suggesting  behaviors such as undereating, binging and purging could be owed to anatomical alterations in parts of the brain. 

breast cancer screening mammography

Commercially available AI increases breast cancer detection by nearly 20%

Results from the world’s largest prospective artificial intelligence study revealed the system could significantly benefit breast cancer screening programs.

Alleviant Medical, a Texas-based medical device company, has received the FDA’s breakthrough device designation and an investigational device exemption (IDE) for its new atrial shunt that treats heart failure without leaving a permanent implant in the body.

FDA sees value in no-implant heart failure device

The new atrial shunt from Alleviant Medical was designed to treat heart failure without leaving a permanent implant behind. The FDA granted the technology its breakthrough device designation and approved additional research. 

Michael Reardon, MD, said monitoring under expansion would have made Acurate Neo2 non-inferior to current TAVR valves in the ACURATE IDE trial.

The primary reason Boston Scientific’s TAVR valve fell short in clinical trial

Michael Reardon, MD, co-principal investigator of the ACURATE IDE trial, discussed updated data on what may have impacted that study's findings.

Sentinel axillary lymph node injected with tattoo ink via ultrasound guidance

Tattoo ink a promising option for localizing sentinel axillary lymph nodes

In some cases, the method even helps to home in on sentinel nodes that may not have been identified during prior biopsy.